Diabetes

Coronavirus disease 2019 (COVID-19) has mandated substantive changes in health care provision to minimize the risk of transmission within health care facilities. Introduction of physical distancing, a heightened focus on hand hygiene and workplace cleanliness, and widespread moves to telehealth provision have been observed (1,2). However, little is known about the impact of the pandemic

People with coronavirus disease 2019 (COVID-19) and preexisting type 1 diabetes (T1D) are at high risk of diabetes-related outcomes such as diabetic ketoacidosis (DKA) and hospitalization (1). For people with elevated glucose levels, infections could further exacerbate the risk of acute complications. As part of the management of T1D, the use of diabetes technology including

The number of patients with diabetes is expected to increase by 51% worldwide within the next 25 years, with diabetes complications resulting in high health costs (1). Consequently, comprehensive diabetes care is essential to control disease progression. Pharmacists are able to contribute to diabetes care in different settings (2,3). However, large randomized controlled trials for

How do I use an at-home test? Instructions will vary depending on the type and brand of test kit. Below are examples of some common at-home tests and how they are performed. Pregnancy Test Used to diagnose pregnancy by checking for a hormone called human chorionic gonadotropin (HCG). HCG is normally only produced during pregnancy.

What is a glucagon blood test? This test measures the amount of glucagon in the blood. Glucagon is a hormone made by the pancreas. It helps control your body’s level of glucose (blood sugar). Glucose is your body’s main source of energy. When glucose levels drop, the pancreas releases glucagon into the bloodstream. This triggers

Abstract OBJECTIVE Disparities in type 1 diabetes related to use of technologies like continuous glucose monitors (CGMs) and utilization of diabetes care are pronounced based on socioeconomic status (SES), race, and ethnicity. However, systematic reports of perspectives from patients in vulnerable communities regarding barriers are limited. RESEARCH DESIGN AND METHODS To better understand barriers, focus

Abstract OBJECTIVE To explore associations between reductions in diabetes distress (DD) and improvements in glycemic outcomes among adults with type 1 diabetes (T1D) in the context of a DD randomized clinical trial. RESEARCH DESIGN AND METHODS Adults with T1D (N = 301) participated in a two-arm trial aimed at reducing DD (DD-focused OnTrack group vs.

Abstract OBJECTIVE To determine the longer-term effects of metformin treatment and behavioral weight loss on gut microbiota and short-chain fatty acids (SCFAs). RESEARCH DESIGN AND METHODS We conducted a 3-parallel-arm, randomized trial. We enrolled overweight/obese adults who had been treated for solid tumors but had no ongoing cancer treatment and randomized them (n = 121)

Insulin was first isolated in 1921 and developed as a therapeutic agent in the 1920s. The initial crude preparations were injected multiple times daily because of their short duration of action. Consequently, there were many attempts to develop insulin preparations with prolonged biological availability in the hope that less frequent once-daily administration would be feasible

Thank you for sharply spotting and kindly bringing to our attention an error in the units of event rates of the LEADER trial in Table 1 of our article (1). As you correctly surmise (2), we failed to notice the different units in this trial from the other trials, also due to the fact that

I read with great interest the recent Perspective by Ferrannini and Rosenstock (1), which provides thoughtful insight on the interpretation of the numerous recent cardiovascular outcome trials (CVOT) in the field of type 2 diabetes. As far as I understand, though, there are some numerical mistakes in both Table 1 and Fig. 2A and B

Diabetic peripheral neuropathy (DPN) is characterized by pain and sensory loss, affecting approximately 50% of patients (1). Early identification and risk factor management are key to limiting progression of DPN. In contrast to retinopathy (retinal fundus imaging) and nephropathy (microalbuminuria) with early disease detection, the 10-g monofilament identifies advanced DPN. Corneal confocal microscopy (CCM) is

Introduction CamAPS FX (CamDiab, Cambridge, U.K.) is a hybrid closed-loop app hosting the Cambridge closed-loop algorithm on an Android smartphone, and it is approved in the European Union for use in children ≥1 year and adults (including during pregnancy) with type 1 diabetes (T1D). The interoperable CamAPS FX app receives glucose data from a compatible

The coronavirus disease 2019 (COVID-19) pandemic has claimed a notable number of deaths in the U.S. The COVID-19 death toll could not wholly explain the substantial increase in all-cause mortality during the pandemic (1), suggesting that the pandemic has indirect impacts on susceptible populations with underlying medical problems, such as cardiovascular diseases (2). Diabetes is

Diabetes-related foot ulcers (DFUs) affect around 20 million people annually and are a leading cause of the global disability burden (1). DFUs are complex to treat, take months to heal, result in poorer quality of life, and place patients at high risk of hospitalization and amputation. Thus, understanding the influence that different factors have on

We read with great interest the leading article by Neeland et al. (1) highlighting the beneficial effects of empagliflozin treatment on several metabolic end points among participants with type 2 diabetes and obstructive sleep apnea (OSA) in the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). In addition,

The impact of the coronavirus disease 2019 (COVID-19) pandemic on amputation incidence in whole populations with diabetes is unknown. Previous reports are restricted to small cohorts from single specialist centers showing varying outcomes, including greater ulcer severity on presentation (1) and increased amputations (2). We aimed to carry out a population-based assessment of lower-limb major

Diabetes is one of the most prevalent and costly health conditions in the U.S. (1), and diet plays a fundamental role in managing the condition effectively. Yet prior research raises concerns about the “food security” of people with diabetes (i.e., whether they have access to healthy, affordable food) (2,3). It is unknown, however, how widespread

Previous studies demonstrated that aggregation of Asians into one group masks the variation in type 2 diabetes prevalence across U.S. Asian subgroups. However, fewer studies have assessed Asian ethnic differences in the risk of other conditions associated with insulin resistance and glucose dysregulation. Furthermore, despite the known association of polycystic ovary syndrome (PCOS) and insulin

The most frequent adverse events associated with sodium–glucose cotransporter 2 (SGLT2) inhibitors are genital infections, with an incidence ranging from 3.7% to 11.4% in clinical trials (1,2). Treatment with SGLT2 inhibitors has also been associated with a modest increase in the risk of urinary tract infections (3). Genito-urinary infections are more frequent in women, particularly

A recent case series of diabetic ketoacidosis (DKA) associated with colonoscopy in sodium–glucose cotransporter 2 inhibitor (SGLT2i)-treated diabetes (1) prompted a clinical alert update to include colonoscopy (2). That update advised colonoscopy cancellation when capillary ketone concentrations are >1.0 mmol/L (if blood gas analysis is unavailable) when SGLT2i have not been withheld for 72 h.

Racial/ethnic inequity exists in all aspects of health care and does not exclude the field of advanced diabetes technology. Despite the recent increase in technological therapeutic options for diabetes management and mounting evidence of positive effects on glycemic outcomes, emerging reports have highlighted that insulin pump and continuous glucose monitor use remain significantly lower in